TREATMENT RELATED SECONDARY MALIGNANCY

This adverse event was reported 203 times

These drugs are most commonly taken by patients reporting TREATMENT RELATED SECONDARY MALIGNANCY:

# Drug Count
0 CYCLOPHOSPHAMIDE 76
1 CYCLOPHOSPHAMIDE FOR INJECTION 76
2 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 76
3 METHOTREXATE 52
4 METHOTREXATE SODIUM 52
5 ETOPOSIDE 45
6 CYTARABINE 34
7 CISPLATIN 31
8 VINCRISTINE SULFATE 28
9 MERCAPTOPURINE 24
See all common drugs associated with TREATMENT RELATED SECONDARY MALIGNANCY

TREATMENT RELATED SECONDARY MALIGNANCY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DACTINOMYCIN 13 0.0059
1 MITOMYCIN 8 0.0022
2 VINBLASTINE SULFATE 4 0.0020
3 BLEOMYCIN SULFATE 16 0.0015
4 MERCAPTOPURINE 24 0.0014
5 MITOXANTRONE HYDROCHLORIDE 8 0.0013
6 DACARBAZINE 9 0.0012
7 VINCRISTINE SULFATE 28 0.0009
8 ETOPOSIDE 45 0.0006
9 CYTARABINE 34 0.0006
See all drugs enriched for association with TREATMENT RELATED SECONDARY MALIGNANCY

TREATMENT RELATED SECONDARY MALIGNANCY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Actinomycin [EPC] 13 0.0059
1 Topoisomerase Inhibitor [EPC] 45 0.0006
2 Alkylating Drug [EPC] 94 0.0004
3 CD33-directed Immunoconjugate [EPC] 1 0.0003
4 Nucleoside Metabolic Inhibitor [EPC] 48 0.0002
5 Platinum-based Drug [EPC] 38 0.0001
6 Folate Analog Metabolic Inhibitor [EPC] 52 0.0001
7 Microtubule Inhibitor [EPC] 14 0.0001
8 CD52-directed Cytolytic Antibody [EPC] 1 0.0001
9 Purine Antimetabolite [EPC] 4 0.0000
See all drug classes enriched for association with TREATMENT RELATED SECONDARY MALIGNANCY